Geron Corporation declined 1.35% in premarket trading, with the company announcing presentations on RYTELO (imetelstat) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. The presentations highlight the potential benefits of RYTELO for patients with lower-risk myelodysplastic syndromes (LR-MDS) and showcase progress in ongoing trials for myelofibrosis (MF).
Comments
No comments yet